SV2B and renal cell carcinoma: Recent studies have demonstrated that these drugs are safe and well‐tolerated after oral administration, highlighting their clinical translational potential for the treatment of TFE3‐RCC.[28, 39] Notably, SV2B is expressed at low levels in other major organs and tissues.